By Matthew Johnson

Nigeria’s ambition to reduce dependence on imported vaccines and establish sustainable domestic production will depend on adequate infrastructure, technology transfer, skilled manpower and long-term investment, as the Federal Government advances plans to strengthen local vaccine manufacturing.

The initiative, being pursued through Biovaccines Nigeria Limited (BVNL), a joint venture between the Federal Government and May & Baker Nigeria Plc, is part of broader efforts to expand the country’s pharmaceutical manufacturing capacity and strengthen its healthcare value chain.

However, funding constraints, inadequate infrastructure, limited technical expertise, quality assurance requirements and uncertainty over market demand remain major challenges that could affect the development and sustainability of Nigeria’s vaccine manufacturing industry.
The challenges were highlighted in a 2026 study published in Health Research Policy and Systems, which identified infrastructure deficiencies, limited technical capacity, inadequate financing and uncertain market mechanisms as significant obstacles to domestic vaccine production in Nigeria.

In September 2026, the Federal Government transferred title documents for two federal properties in Lagos to BVNL as part of its equity contribution to the partnership, in a move expected to support investment, international collaboration and the development of local vaccine production facilities.

The properties, located at 445 Herbert Macaulay Way and No. 1 University Road, Yaba, Lagos, are expected to strengthen the company’s capacity to attract financing and technical partners for its manufacturing ambitions.
Beyond providing facilities, experts say Nigeria will need to establish the technical, financial and regulatory foundations required to sustain production and ensure that locally manufactured vaccines meet stringent international standards.

Vaccine manufacturing is a complex process that requires specialised facilities, reliable electricity, advanced equipment, highly trained scientists and engineers, effective quality-control systems and dependable cold-chain logistics to preserve the safety and effectiveness of products.

These requirements make sustained investment essential, particularly as manufacturers must maintain production standards while meeting regulatory requirements and competing in a market dominated by established international producers.
Technology transfer, workforce development
Technology transfer is expected to play a critical role in Nigeria’s efforts to establish a viable vaccine manufacturing industry.

International partnerships could provide local manufacturers with access to technical knowledge, production processes and operational expertise needed to develop vaccines, operate manufacturing facilities and meet applicable regulatory standards.
However, the sustainability of such partnerships will depend on their ability to build local capacity rather than leave domestic manufacturers reliant on external technical support.
Developing a skilled workforce will also be essential to the process.

Nigeria will need specialists in biotechnology, microbiology, pharmaceutical engineering, production management and quality assurance to operate manufacturing facilities, maintain production standards and support research and development.
Without adequate investment in specialised training and technical capacity, the country could struggle to translate infrastructure development and international partnerships into consistent domestic vaccine production.

Market demand, financing concerns
Financing and market sustainability are other critical considerations for the initiative.
Vaccine manufacturing requires substantial capital investment, while facilities must maintain stringent quality standards and reliable production systems regardless of fluctuations in demand.

Stakeholders have therefore highlighted the importance of predictable market demand, noting that government procurement policies and long-term purchasing commitments could help local manufacturers sustain operations, provided their products meet the required safety, quality and efficacy standards.

A dependable domestic market could also give manufacturers greater certainty when planning production, investing in equipment and expanding their operations.
However, government support would need to be complemented by private-sector investment, research partnerships and appropriate financing arrangements to ensure that local production remains commercially and operationally sustainable.

Nigeria’s efforts to strengthen domestic healthcare manufacturing also have implications beyond vaccines, particularly as the country seeks to develop local capacity for producing essential medical products and reduce exposure to disruptions in international supply chains.

Nigeria could draw lessons from existing healthcare manufacturing initiatives, including Codix Bio, a Nigerian in-vitro diagnostics manufacturer.
In May 2025, the World Health Organisation (WHO) and the Medicines Patent Pool announced Codix Bio as the first sublicensee under an agreement supporting the local development and manufacture of rapid diagnostic tests in collaboration with SD Biosensor.
Although diagnostic manufacturing differs from vaccine production in terms of technology, processes and regulatory requirements, the arrangement demonstrates how international partnerships can facilitate technology transfer and strengthen domestic healthcare manufacturing capacity.

Similar collaborations could support Nigeria’s vaccine manufacturing ambitions by combining international technical expertise with local investment, workforce development and manufacturing capabilities.
For such partnerships to deliver lasting benefits, however, the transfer of knowledge and skills would need to be accompanied by sustained investment in infrastructure, research and development, regulatory capacity and local expertise.

Regulatory standards, African market
The country’s ambition to supply vaccines to other African markets will also depend on its ability to maintain consistent production, demonstrate product quality and satisfy the regulatory requirements of destination countries.
Manufacturers must be able to demonstrate that their products meet established standards for safety, quality and efficacy before they can be approved for use.

Meeting these requirements will require an effective regulatory framework, reliable testing facilities and quality-assurance systems capable of supporting production and facilitating market access.
Beyond domestic regulatory approval, access to regional markets will depend on compliance with the relevant requirements in destination countries and the ability to maintain dependable supplies.

For Nigeria to develop a sustainable vaccine industry, government investment will therefore need to be complemented by private-sector participation, international technical partnerships, adequate financing and a regulatory environment that supports quality manufacturing.

The success of the BVNL initiative will ultimately depend on the country’s ability to translate its investment commitments into functional manufacturing capacity, produce essential vaccines reliably, meet domestic healthcare needs and sustain an industry capable of serving wider African markets.